论文部分内容阅读
为了评价环孢素A(CSA)长期应用治疗系统性红斑狼疮(SLE)的疗效,37例符合下列条件的SLE患者纳入本研究:①符合美国风湿病学会修改的SLE诊断标准;②既往对皮质类固醇或细胞毒药物的治疗反应欠佳或无反应;③临床上至少有2个系统受损的表现;④近一个月内类固醇用量稳定者。有下列之一的患者将被剔除,血清肌酐水平>1.5mg/dl;高血压;有癌症或癌症病史及近3个月接受抗代谢药物治疗的患者。疗效评定标准主要依据SLE活动程度测定(SLAM)记分,包括24种临床表现和8项实
To evaluate the long-term efficacy of cyclosporin A (CSA) in the treatment of systemic lupus erythematosus (SLE), 37 SLE patients with the following criteria were included in the study: ① meet the American College of Rheumatology modified SLE diagnostic criteria; ② previous cortical Steroid or cytotoxic drug treatment response is poor or no response; ③ clinical at least 2 system damage performance; ④ steroid dosage within a month of stability. Patients with one of the following will be rejected, serum creatinine level> 1.5 mg / dl; hypertension; patients with a history of cancer or cancer and antimetabolite therapy for nearly 3 months. The efficacy evaluation criteria mainly based on SLE activity measure (SLAM) score, including 24 clinical manifestations and 8 real